Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial
Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial. // The Lancet Gastroenterology & Hepatology. – URL: https://www.sciencedirect.com/science/article/pii/S2468125326002608?dgcid=rss_sd_all
Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Gastroenterology & Hepatology. https://www.sciencedirect.com/science/article/pii/S2468125326002608?dgcid=rss_sd_all
“Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial.” The Lancet Gastroenterology & Hepatology.
@article{article68408,
title = {Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial},
journal = {The Lancet Gastroenterology \& Hepatology},
url = {https://www.sciencedirect.com/science/article/pii/S2468125326002608?dgcid=rss_sd_all}
}